Holen Sie sich die Stockscreener-App
1.91
0.53%
0.01
Schlusskurs vom Vortag:
$1.90
Offen:
$1.9
24-Stunden-Volumen:
18,521
Relative Volume:
0.29
Marktkapitalisierung:
$13.28M
Einnahmen:
$2.35M
Nettoeinkommen (Verlust:
$-2.56M
KGV:
-4.2624
EPS:
-0.4481
Netto-Cashflow:
-
1W Leistung:
-13.18%
1M Leistung:
-11.16%
6M Leistung:
-0.52%
1J Leistung:
-2.14%
1-Tages-Spanne:
$1.90
$1.9856
1-Wochen-Bereich:
$1.80
$2.2099
52-Wochen-Spanne:
$1.50
$2.483
Immuron Limited Adr Stock (IMRN) Company Profile
Firmenname
Immuron Limited Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie IMRN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMRN
Immuron Limited Adr
|
1.98 | 12.79M | 2.35M | -2.56M | 0 | -0.4481 |
|
VRTX
Vertex Pharmaceuticals Inc
|
420.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
630.36 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.38 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
811.48 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
179.68 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Immuron Limited Adr Aktie (IMRN) Neueste Nachrichten
[6-K] Immuron Ltd Current Report (Foreign Issuer) - Stock Titan
Immuron Announces Clinical Trial Update - GlobeNewswire Inc.
Immuron Announces Clinical Trial Update - Sahm
Immuron CEO to Present at AusBiotech Invest 2025 Conference - TipRanks
IMRN furnishes 6-K with ASX updates and Exhibit 99.1 - Stock Titan
Immuron Ltd. (ADR) (US45254U1016.SG) Stock Price, News, Quote & History - Yahoo
Immuron Limited Announces 2025 Annual General Meeting - MSN
[6-K] Immuron Ltd Current Report (Foreign Issuer) | IMRN SEC FilingForm 6-K - Stock Titan
Immuron Submits IMM-529 IND to FDA - markets.businessinsider.com
Immuron (IMRN) Seeks FDA Green Light for Novel C. diff Treatment - GuruFocus
Immuron Limited Submits IND Application to FDA for IMM-529 to Combat Clostridioides difficile Infection - Quiver Quantitative
$400M Market Potential: Immuron's C. Difficile Drug IMM-529 Heads to FDA as Company Advances 3 Key Programs - Stock Titan
Immuron Limited Secures Auditor Consent for Financial Filings - MSN
What analysts say about Immuron Limited ANW stockBear Market Strategies & Low Risk Capital Gains - earlytimes.in
Is Immuron Limited Depositary Receipt forming a reversal patternJuly 2025 Earnings & Low Risk Entry Point Guides - newser.com
Is it too late to sell Immuron Limited Depositary ReceiptMarket Activity Report & Fast Moving Trade Plans - Newser
Does Immuron Limited Depositary Receipt fit your quant trading modelJuly 2025 Price Swings & High Win Rate Trade Tips - Newser
Statistical indicators supporting Immuron Limited Depositary Receipt’s strengthPortfolio Risk Summary & Real-Time Sentiment Analysis - Newser
What institutional flow reveals about Immuron Limited Depositary ReceiptEarnings Growth Summary & Entry Point Strategy Guides - Newser
Immuron Limited Depositary Receipt stock trend forecastWeekly Investment Summary & AI Optimized Trading Strategy Guides - Newser
Visualizing Immuron Limited Depositary Receipt stock with heatmapsAI Trading Forecast Based on Big Data - Newser
BNY Mellon Increases Stake in Immuron Limited - TipRanks
Immuron Limited Announces Cessation of Securities - TipRanks
What drives Immuron Limited Depositary Receipt stock priceHigh-yield capital appreciation - jammulinksnews.com
Immuron - GlobeNewswire Inc.
Immuron Crushes Sales Forecast: North America Soars 76%, Global Revenue Breaks Records at $7.3M - Stock Titan
immuron ltd files for quotation of securities on ASX By Investing.com - Investing.com South Africa
immuron ltd files for quotation of securities on ASX - Investing.com
IMRNImmuron Ltd Latest Stock News & Market Updates - Stock Titan
Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS) - BioSpace
Immuron: Targeted oral antibodies to treat infectious diseases - Innovation News Network
Immuron Travelan® continued strong sales growth - FinancialContent
Immuron: US FDA provides favourable feedback ahead of investigational new drug application for IMM-529 - Proactive financial news
Immuron Plans Phase 2 Trial for IMM-529 following FDA review - GlobeNewswire
Immuron requests pre-IND meeting for IMM-529 with FDA filing - FinancialContent
symbol__ Stock Quote Price and Forecast - CNN
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.34% - Investing.com
Immuron Limited Announces Closing of $20.0 Million Registered Direct Offering - Stock Titan
The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates - Yahoo Finance
IMC Reports Rising Revenues & Eyes Colitis Market - Next Investors
Immuron Limited Issues Correction to Misleading Halt Announcement Headline - GlobeNewswire
IMC Stock Price and Chart — ASX:IMC - TradingView
Immuron Limited (IMRN) stock price, news, quote and history - Yahoo! Finance UK
Finanzdaten der Immuron Limited Adr-Aktie (IMRN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.66%
0.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):